Effects of Fluticasone Propionate on Asthma
Author Information
Author(s): S. E. Overbeek, J. M. Bogaard, I. M. Garrelds, F. J. Zijlstra, P. G. H. Mulder, H. C. Hoogsteden
Primary Institution: University Hospital Rotterdam Dijkzigt and Erasmus University, Rotterdam, the Netherlands
Hypothesis
Fluticasone propionate downregulates arachidonic acid metabolites in bronchoalveolar lavage fluid and influences methacholine dose-response curves in asthma.
Conclusion
Fluticasone propionate significantly decreased sensitivity to methacholine and the maximum airway narrowing response, while also reducing PGD2 levels in bronchoalveolar lavage fluid.
Supporting Evidence
- Fluticasone propionate significantly decreased sensitivity to methacholine after 12 weeks.
- PGD2 levels in bronchoalveolar lavage fluid decreased significantly in the fluticasone group.
- Changes in airway responsiveness were not correlated with changes in most arachidonic acid metabolites.
Takeaway
This study found that a medication called fluticasone helps people with asthma breathe better by changing how their airways respond to certain triggers.
Methodology
The study was a randomized, double-blind, placebo-controlled trial involving 33 stable non-smoking asthmatics who received either fluticasone propionate or placebo for 12 weeks.
Limitations
The study did not find significant changes in most arachidonic acid metabolites except for PGD2, and the correlation between changes in sensitivity and PGD2 levels was not established.
Participant Demographics
33 stable non-smoking asthmatics (23 male, median age 26 years, range 18 to 56 years).
Statistical Information
P-Value
0.058 for PGD2
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website